serratiopeptidase serratiopeptidase serratiopeptidase (serratia e-15 protease, also known as serralysin, serrapeptase, serratiapeptase, serratia peptidase, serratio peptidase, or serrapeptidase) is a proteolytic enzyme (protease) produced by enterobacterium serratia sp. e-15, now known as serratia marcescens atcc 21074. this microorganism was originally isolated in the late 1960s from silkworm (bombyx mori l.) intestine. serratiopeptidase is present in the silkworm intestine and allows the emerging moth to dissolve its cocoon. serratiopeptase is produced by purification from culture of serratia e-15 bacteria. it is a member of the peptidase m10b (matrixin) family. serralysincrystal structure of serralysin with co-ordinated zinc (grey) and calcium (white). rendered from pdb 1sat.identifiersec no.3.4.24.40cas no.70851-98-8 databasesintenzintenz viewbrendabrenda entryexpasynicezyme viewkeggkegg entrymetacycmetabolic pathwaypriamprofilepdb structuresrcsb pdb pdbe pdbsumsearchpmcarticlespubmedarticlesncbiproteins serratiopeptidaseidentifiersorganismserratia sp. e-15symbolspro_0210entrez5605823pdb1srpuniprotp07268other dataec number3.4.24.40search forstructuresswiss-modeldomainsinterpro health claims some alternative medicine proponents claim that serratiopeptidase is beneficial for pain and inflammation but "existing trials small and generally of poor methodological quality." online medical journal bandolier (specializing in evidence-based thinking about healthcare) published an article (in about 2001) in response to a reader's enquiry about serratiopeptidase. after searching pubmed and the cochrane library "to see if there are any randomised, controlled trials", the article stated that the "evidence on serratiopeptidase being effective for anything is not based on a firm foundation of clinical trials." the search found 34 publications in the medical databases covered that addressed the efficacy of serratiopeptidase, of which several were found to be animal experiments, personal letters, uncontrolled trials or those with inadequate or nonexistent randomisation. the article warned against ignoring safety issues with use of biological agents. no studies were found to have been conducted on the efficacy of serratiopeptidase as treatment for back pain, heart attack, stroke, or asthma. of the 10 medical conditions with randomized-evidence studies on file in connection with serratiopeptidase, the quality or construction of the trial studies was described as "generally poor".